Mylabris has exhibited a range of pharmacological activities, such as antitumor, anti-inflammatory, leukocytosis, immune function enhancement, pest resistance, and treatment of skin diseases through inhibition of tumor cell proliferation and metastasis, modulation of immune responses and apoptotic pathways through inhibiting PP1/PP2A, regulated PI3K/AKT/mTOR, ERK/MAPK, JAK2-STAT3, and other signaling pathways. The gene discussed is MTOR; the disease is neoplasm.